allogeneic bone marrow transplantation is the only definie cure in thalassemia and its most important complication is chronic graft-versus-host disease (cgvhd). we analysed the incidence of cgvhd and its associated risk factors in a group of 89 iranian thalassemic patients of hla-identical sibling transplants surviving at least 90 days after transplantation.in the majority of cases (39) cgvhd o...

background: the study attempts to assess the relationship between chimerism analysis using polymerase chain reaction of short tandem repeat (str) and the incidence of chronic graft versus host disease (gvhd) as well as survival. methods: the retrospective cohort included all patients who received allo-hsct between 2005 to 2013. data collected by day +100 were reviewed in terms of the incidence ...

background: chronic graft versus host disease (cgvhd) is one of the most serious potential complications of allogeneic bone marrow transplantation. study design and method: we analyzed the incidence of cgvhd and its associated risk factors in a group of 161 iranian recipients of hla-identical sibling transplants, with at least 90 days post-transplantation survival. in the majority of cases (n=7...

Chronic graft-versus-host disease (GVHD) is an important complication of bone marrow transplantation. We analyzed risk factors for chronic GVHD in 2,534 recipients of HLA-identical sibling transplants surviving at least 90 days after transplantation. The actuarial probability of developing chronic GVHD within three years posttransplant was 46% +/- 3% (95% confidence interval). The most importan...

The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6% (95% confidence interval [CI], 0%-13%), and clinical extensive chronic GVHD in 71% (95% CI, 61%-80%). The cumulative i...

The incidence, characteristics, risk factors for, and impact of chronic graft-vs-host disease (GVHD) were evaluated in a consecutive series of 116 evaluable HLA-identical blood stem cell transplant recipients. Minimum follow-up was 18 months. Limited chronic GVHD occurred in 6% (95% confidence interval [CI], 0%-13%), and clinical extensive chronic GVHD in 71% (95% CI, 61%-80%). The cumulative i...

Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoietic cell transplantation (HCT) was called chronic GVHD, even if the clinical manifestations were indistinguishable from acute GVHD. In 2005, the National Institutes of Health (NIH) sponsored a consensus conference that proposed new criteria for diagnosis and classification of chronic GVHD for clinical trials. Accordi...

Antigen-stimulated naïve T cells differentiate into effector and memory cells, of which resident (TRM) reside permanently in organ tissues. Involvement TRM has been indicated pathological conditions various skin diseases. CD122, is the β chain subunit interleukin (IL)-2 IL-15 receptors, expressed on immune including cells. To investigate whether CD122 signaling CD8+ mediates development mucocut...

To assess the influence of graft-versus-host disease (GVHD) on recurrent leukemia and survival after allogeneic marrow transplantation, we studied 1,202 patients with acute nonlymphocytic leukemia (ANL), acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) given unmodified marrow grafts from HLA-identical siblings. Proportional hazards regression models using acute GVHD and ...

Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after allogeneic bone marrow transplantation (BMT), but the pathophysiology of chronic GVHD still remains poorly understood. We tested the hypothesis that the impaired thymic negative selection of the recipients will permit the emergence of pathogenic T cells that cause chronic GVHD. Lethally irradiated...